Softwr

AI · head to head

LatchBio vs Terra

LatchBio logo

LatchBio

AI

AI agents that run bioinformatics analyses, from a company that pivoted from workflow hosting

From
On request
Rated
-
Full reviewWebsite
Terra logo

Terra

Research

Open biomedical research platform for genomic analysis, priced only by the cloud you consume

From
Free
Rated
-
Full reviewWebsite

The short version

  • Only Terra has a free tier, so it costs nothing to try first.
  • Each has a real cost: LatchBio the company has pivoted from hosted bioinformatics workflows to AI agents, so organisations that adopted the earlier SDK and workflow product are now on a line that is no longer the strategic focus.; Terra the absence of a licence fee hides the real cost driver: an idle notebook virtual machine left running overnight, or a workspace bucket full of intermediate workflow outputs, quietly consumes grant money with no vendor invoice to prompt a review.
  • They diverge on capability: LatchBio covers Agent driven analysis, Terra covers No platform licence fee.
  • Prices and features above were last checked on 31 August 2026.

Where they differ

Only the attributes on which LatchBio and Terra actually diverge.

Attributes where LatchBio and Terra differ
AttributeLatchBioTerra
Starting priceOn requestFree
Pricing modelquoteOpen source, no licence fee
Free tierNoYes
PlatformsWebWeb, Google Cloud, Microsoft Azure
CategoryAIResearch

Identical on both: user rating (Not yet rated).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in LatchBio

  • Agent driven analysis
  • Multi assay support
  • Published benchmarks
  • White labelled portals
  • Common file format handling
  • Managed compute

Only in Terra

  • No platform licence fee
  • Cloud pass-through billing
  • WDL workflow execution
  • Notebook environments
  • Controlled-access data
  • Workspace sharing
  • Compliance posture
  • Multi-cloud

What people use each for

The jobs each tool is most often brought in to do.

LatchBio

  • A small biotech with sequencing data and no bioinformatician who needs a first pass differential expression or cell type annotation quicklynot Terra
  • An assay or kit vendor that wants to give customers an analysis portal under its own branding rather than shipping raw filesnot Terra
  • A wet lab scientist who wants to explore a dataset interactively before commissioning a formal analysis from a core facilitynot Terra
  • A research group benchmarking agent produced analyses against its own established pipeline to decide how much routine work can be delegatednot Terra

Terra

  • A genomics lab running whole-genome alignment and variant calling pipelines without provisioning or maintaining a local clusternot LatchBio
  • A consortium sharing controlled-access human data across institutions where the data cannot be copied to each sitenot LatchBio
  • A health system analysing patient genomic data under a HIPAA business associate agreementnot LatchBio
  • A federal or federally funded project needing FedRAMP Moderate authorisation for its analysis environmentnot LatchBio

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

LatchBio

  • The company has pivoted from hosted bioinformatics workflows to AI agents, so organisations that adopted the earlier SDK and workflow product are now on a line that is no longer the strategic focus.
  • Agent generated analysis code has to be validated by someone who could have written it, which inverts the value proposition for the small labs that most need it and cannot check the output.
  • No pricing is published, so the cost of routine agent analysis at team scale cannot be estimated without contacting sales, and compute billed through the platform makes the bill usage dependent.
  • Regulated use is a poor fit: an agent that writes non deterministic analysis code is difficult to validate under GxP, so this is a research tool rather than something that will sit in a regulated diagnostic or submission workflow.
  • The vendor publishes its own benchmarks, which is more than most competitors do, but self reported benchmarks on selected datasets are not a substitute for testing the agent on your own data before committing.

Terra

  • The absence of a licence fee hides the real cost driver: an idle notebook virtual machine left running overnight, or a workspace bucket full of intermediate workflow outputs, quietly consumes grant money with no vendor invoice to prompt a review.
  • Cost governance is entirely the customer responsibility, and grant-funded groups without a cloud engineer routinely overspend before anyone reads the Google or Azure bill in enough detail to find the cause.
  • It assumes genuine bioinformatics competence: writing or adapting WDL workflows, managing data tables and debugging failed tasks are all on you, so a wet lab without computational staff cannot use it productively.
  • Feature parity between the Google Cloud and Azure deployments is not identical, so a decision on cloud provider constrains which capabilities and datasets you can reach and is expensive to reverse later.
  • It is a research platform rather than a regulated clinical system: it is not a validated GxP environment and does not carry the qualification package a diagnostic or submission workflow would require, so clinical use needs additional infrastructure and validation you provide yourself.

Pricing, plan by plan

LatchBio

On request
  • LatchBio Platform$undefined/year
    • Quoted through a sales process
    • Interactive sandbox available for trying the agent before contracting
    • Enterprise and white labelled portal deployments priced separately

Terra

Free
  • Terra platformFree
    • No charge for the platform, administration, security controls or frontline support
    • Workspaces, workflow execution and notebook environments included
    • Available on Google Cloud and Microsoft Azure
  • Cloud consumption$undefined/month
    • Google Cloud or Azure charges passed through at cost with no markup
    • Running notebook virtual machines around 0.22 USD per hour, roughly 0.027 USD per hour when paused
    • Storage billed continuously on workspace buckets and intermediate workflow outputs

Which should you pick?

Choose LatchBio if

  • You need agent driven analysis.
  • You also want multi assay support.
LatchBio review

Choose Terra if

  • You need no platform licence fee.
  • You want to start without paying.
  • You work on Web, Google Cloud, Microsoft Azure.
  • You also want cloud pass-through billing.
Terra review

Questions people ask

Is LatchBio or Terra better?
Neither clearly leads. LatchBio starts at On request and Terra at Free, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, LatchBio or Terra?
Terra has a free tier; the other does not. Paid plans start at On request for LatchBio and Free for Terra.
Does LatchBio or Terra run on more platforms?
LatchBio runs on Web. Terra runs on Web, Google Cloud, Microsoft Azure.
Can I use Terra for free?
Yes. Terra has a free tier, so you can try it without paying. LatchBio starts at On request.
What is LatchBio best used for?
LatchBio is most often used for a small biotech with sequencing data and no bioinformatician who needs a first pass differential expression or cell type annotation quickly, an assay or kit vendor that wants to give customers an analysis portal under its own branding rather than shipping raw files, a wet lab scientist who wants to explore a dataset interactively before commissioning a formal analysis from a core facility, a research group benchmarking agent produced analyses against its own established pipeline to decide how much routine work can be delegated. Of those, a small biotech with sequencing data and no bioinformatician who needs a first pass differential expression or cell type annotation quickly and an assay or kit vendor that wants to give customers an analysis portal under its own branding rather than shipping raw files are not what Terra is typically brought in for.
What can LatchBio do that Terra cannot?
LatchBio covers Agent driven analysis, Multi assay support, Published benchmarks, White labelled portals. Terra covers No platform licence fee, Cloud pass-through billing, WDL workflow execution, Notebook environments.

Answered from the vendors’ own pages

LatchBio: Is LatchBio still selling the original workflow platform?

The company is now led by agent.bio and its agent products. Buyers evaluating the older Python SDK workflow platform should confirm current support directly.

Terra: Is Terra really free?

The platform is. There is no licence fee. Everything you pay is Google Cloud or Azure compute, storage and egress, passed through at cost.

LatchBio: Can I try it before buying?

Yes. There is an interactive sandbox where you can upload data and run the agent before entering a sales conversation.

Terra: What actually drives the bill?

Running virtual machines and stored data. Pausing notebooks drops a virtual machine from about 0.22 to about 0.027 dollars an hour, and deleting intermediate workflow outputs is the other main saving.

LatchBio: Is it suitable for regulated work?

Not really. Non deterministic agent generated code is hard to validate under GxP, so treat it as a research and exploration tool.

Terra: Can I use it with protected health information?

Yes. Terra signs HIPAA business associate agreements and GDPR data processing agreements, and the Azure deployment holds FedRAMP Moderate authorisation.

LatchBio: What data types does it handle?

Single cell RNA sequencing, spatial transcriptomics, epigenomics, proteomics and pharmacology data, ingesting FastQ, H5AD and spreadsheet formats.

Terra: Is it validated for clinical or GxP use?

No. It is a research platform. Regulated clinical or submission workflows need validation and controls you build yourself.

Share

Related pages

More on LatchBio

More on Terra

Keep looking

Other head to heads